Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Apply
Emavusertib & Zanubrutinib
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step